Harold S. Parnes, MD, FACR
A graduate of the Accelerated Biomedical BA-MD Program at State University of New York, Downstate Medical Center, Dr. Parnes is double board certified in Radiology and Neuroradiology. After completing an internship in Internal Medicine and a Residency in Diagnostic Radiology all at Long Island College Hospital in Brooklyn, he served as Chief Resident and then completed a Neuroradiology Fellowship at SUNY Stony Brook Medical Center. Dr. Parnes is an Adjunct Clinical Assistant Professor of Radiology, SUNY School of Medicine, Department of Radiology, Stony Brook New York. He was appointed Director of Neuroradiology at Queens Hospital Center in Jamaica, New York from 1992-1996. Dr. Parnes served as the President of the Alumni Association of the College of Medicine and is the current Chairman of the Board of Trustees at SUNY Downstate Medical Center, College of Medicine Alumni Association. He is the President and Founder of the BA-MD Alumni Affiliate and a Past President of the Kings County Medical Society.
Awarded a Fellowship by the American College of Radiology in 2011, Dr. Parnes is the recipient of many academic honors and awards, including the Harry Z. Mellins, M.D. Master Teacher Award in Radiology, Downstate Medical School. He is an active member of numerous Professional and Specialty Organizations including MSSNY, The American College of Radiology, The Radiological Society of North America, The American Society of Pediatric Neuroradiology, Senior Member of the American Society of Neuroradiology, a member of the American Society of Head and Neck Radiology and a member of the Society of Spine Radiology among others. Dr. Parnes has been in private practice since 1996 as President and Medical Director of Omega Diagnostic Imaging in Sheepshead Bay, Brooklyn.
John M. Amatruda, M.D. FACE
A graduate of Yale University, Dr. Amatruda received his MD degree from the Medical College of Wisconsin and did his internship and residency in Internal Medicine and Fellowship in Endocrinology and Metabolism at The Johns Hopkins Hospital. He is board certified in internal medicine and in Endocrinology and Metabolism. Dr. Amatruda was a Professor of Medicine at The University of Rochester School of Medicine where he was Director of the Clinical Research Center. He left the University of Rochester to start and run a drug discovery group at Bayer Corporation where he was Vice President and Therapeutic Area Research Head as well as an Adjunct Professor of Medicine at Yale University School of Medicine. He assisted in the approval of Acarbose and his group put several compounds into clinical development.
Dr. Amatruda left Bayer to become the Vice President and Therapeutic Area Head for Metabolism and Atherosclerosis at Merck & Co., Inc.. This group was responsible for the approval of 3 drugs, Vytorin, Januvia, and Janumet. He was also interim Therapeutic Area Head for Cardiovascular. Most recently Dr. Amatruda was Senior Vice President and Franchise Head for Diabetes and Obesity and a member of the Research Management Committee. He retired from Merck in Nov 2009 and is currently a consultant, is on several Boards of Directors, is a founder in biotech companies and an Adjunct Professor of Medicine at Yale University. He continues to see patients in a teaching capacity. Dr Amatruda is an author on over 160 publications.
Makarand Jawadekar, Ph.D.
Currently an independent Pharmaceutical Professional, Dr. Jawadekar worked at Pfizer, Inc. for 28 consecutive years. He worked as a Director, Portfolio Management, was responsible for Drug Delivery Technology Assessment where developed extensive experience creating and cultivating external partnerships and alliances for drug delivery technologies. He began his carreer at Pfizer Centeral Research in 1982 after having ocmpleted his PhD. In Pharmeuetics at the University of Minnesota. Dr. Jawadekar was honored with an honorary D.Sc. degree by DYP Mumbai Univeristy, recommended by the President of India in 2011.
His experience with Pfizer R&D includes Solids R&D, Drug Product formulation/Dosage Form/Drug Delivery development, Clinical Trials Supply Manufacturing, Scale-up and Technology Transfer, Pharma R&D outsourcing, as well as Pharmacy areas. He managed several functions/groups within R&D and was the Bench Scientist who worked on the challenging Sertraline (ZOLOFT) tablets formulation which became a multibillion dollar product for many years for Pfizer, Inc. He was the recipient of the "M.L. Khorana Memorial Lecture of the Year Award" at IPC held in New Delhi, India, in 2001. He was invited to join President George W. Bush's trade delegation to India during March 2006 and traveled to India with Pfizer Global R&D President Dr. John LaMattina during 2007 to visit 8 cities in India to view and assess the Pharmaceutical R&D landscape. Dr. Jawakadar represented Pfizer at BioAsia 2009 with Pfizer R&D President, Dr. Martin Mackay in 2009 and served as a Vice President of Asia Pacific American Colleague Resource Group at Pfizer for many years.
Richard Pittner, Ph. D.
With over 25 years of expertise in the discovery, validation, development and in-licensing of novel therapeutics and technologies, Dr. Pittner is currently a consultant and is active as a startup advisor and technology incubator in San Diego. Dr. Pittner co-founded OXT-Therapeutics, focused on the development of an oxytocin-based portfolio for metabolic disease, where he is acting Chief Development Officer. He co-founded an incubator group, BioShore Partners, which has recently progressed 2 product concepts into newly incorporated startups - Abvance and Aquros. Additionally, he is an advisor (acting SVP) to CPC/Xinbang in evaluating/in-licensing peptide therapeutic programs for the Chinese market.
Dr. Pittner worked several years at Eli Lilly and and Pfizer where he led External R&D efforts, identifying, evaluating and in-licensing external drug assets. Previously, he worked for 15 years at Amylin as Head of Discovery Biology developing novel peptide therapeutics for metabolic diseases (including Byetta and Symlin). Dr. Pittner holds a number of patents, is the co-author of over 40 publications and received his Ph.D from University of Nottingham.
Robert E. Silverman, MD, PhD, FACP
A 21-year (1992-2013) veteran of Merck & Co., Dr. Silverman reached the level of Executive Director in the Department of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories. During this time, he oversaw the submission and regulatory authority interactions for 9 New Drug Applications (NDAs)/World-wide Marketing Applications (WMAs), more than 50 major supplemental NDAs/WMAs, more than 30 U.S. INDs, and more than 50 U.S. FDA conferences/meetings. Dr. Silverman was eight years (1984-1992) at the NIH as an extramural Branch Chief (Diabetes, NIDDK). His medical and scientific training included an MD and PhD (Biological Chemistry) from Washington University in St. Louis School of Medicine (1972-1978), medical residency at Yale University (1978-1981), and subspecialty fellowship (Endocrinology and Metabolism) at the NIH (1981-1984).
Currently, Dr. Silverman is an independent, individual consultant providing assessment, advice, and assistance to therapeutics developers on the strategic regulatory aspects of the development of novel therapeutics encompassing early development, initial registration/approval and post-approval life-cycle management of their projects including their interaction with governmental regulatory authorities.